ILC2 Functional Regulation Mechanisms

Scope

This topic page organizes mechanisms that regulate ILC2 function in the current ILC_in_lung wiki. It focuses on upstream epithelial alarmins, lipid mediators, costimulatory/checkpoint pathways, adaptive-immunity feedback circuits, metabolic programs, neuroimmune signals, cytokine-driven plasticity, and infection-conditioned niche effects.

This page is a regulation map. For disease outcomes, see ILC2 Roles In Pulmonary Disease.

Evidence tags

#cell/ILC2 #tissue/lung #assay/flow #assay/scRNAseq #assay/in_vivo #assay/in_vitro #outcome/airway_hyperresponsiveness #outcome/infection #outcome/repair #axis/ILC_airway_inflammation #axis/ILC_lung_infection #axis/ILC_plasticity

Confidence snapshot

High confidence: epithelial alarmins, especially IL-33 and IL-25, are central organizing signals for many ILC2 lung/asthma models in this source set.
High confidence: metabolic state is a recurring regulator of ILC2 effector function, including autophagy, glycolysis/HIF-1alpha, mitochondrial activity, and PD-1-linked metabolism.
Medium confidence: lipid mediators, neuropeptides, neurotransmitters, costimulatory pathways, and checkpoint pathways shape ILC2 activity in context-specific ways.
Medium confidence: infection can reprogram ILC2 output and alter macrophage/niche consequences.
Low confidence: mechanisms from gut or nasal inflammation should not be assumed to operate identically in lung ILC2s.
Medium confidence: extrapulmonary ILC2 regulatory context includes aryl-hydrocarbon-receptor/AHR and RXRgamma nuclear-receptor restraint, RORalpha developmental lineage boundaries, ADM2 tissue-protective neuroimmune signaling, and tuft-cell IL-17RB control of IL-25 bioavailability; these refine regulatory vocabulary but should stay tissue-labeled.

Established observations

Epithelial alarmins and cytokine activation

IL-33/ST2 and IL-25 appear repeatedly as upstream ILC2 activation axes in asthma, allergen, and viral airway models.
Kinetics of the accumulation of group 2 innate lymphoid cells in IL-33-induced and IL-25-induced murine models of asthma a potential role for the chemokine CXCL16 links IL-33/IL-25-driven models to ILC2 accumulation and CXCL16 as a candidate recruitment or positioning cue.
IL-1beta prevents ILC2 expansion, type 2 cytokine secretion, and mucus metaplasia in response to early-life rhinovirus infection in mice supports IL-1beta as a negative regulator of ILC2 expansion and type 2 output in early-life rhinovirus-like disease.
Tuft cell IL-17RB restrains IL-25 bioavailability and reveals context-dependent ILC2 hypoproliferation refines the IL-25-ILC2 axis by showing epithelial control of IL-25 bioavailability in a gut tuft-cell circuit.
IL-9 and Blimp-1 protect the transcriptional identity of group 2 innate lymphocytes in allergic asthma adds a lung allergic-asthma state-fidelity branch in which IL-33/IL-25-induced IL-9 upregulates Blimp-1 to maintain ILC2 type 2 identity while restraining IFN-gamma/TNF programs.
IL-1beta, IL-23, and TGF-beta drive plasticity of human ILC2s towards IL-17-producing ILCs in nasal inflammation supports a cytokine-driven plasticity branch, but nasal inflammation should stay context-labeled.

Lipid mediators and inflammatory amplifiers

Lung type 2 innate lymphoid cells express cysteinyl leukotriene receptor 1 which regulates TH2 cytokine production supports cysteinyl leukotriene receptor signaling as a lung ILC2 regulatory mechanism.
Cysteinyl leukotriene E(4) activates human group 2 innate lymphoid cells and enhances the effect of prostaglandin D(2) and epithelial cytokines supports synergistic lipid/epithelial cytokine activation of human ILC2s.
Fevipiprant, a selective prostaglandin D2 receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function supports DP2 antagonism as an upstream inhibitory branch that blocks PGD2-driven migration, aggregation, and cytokine output in human ILC2s.
Lipid-Droplet Formation Drives Pathogenic Group 2 Innate Lymphoid Cells in Airway Inflammation supports lipid-droplet biology as a pathogenic ILC2-state mechanism.
Tissue-Restricted Adaptive Type 2 Immunity Is Orchestrated by Expression of the Costimulatory Molecule OX40L on Group 2 Innate Lymphoid Cells supports OX40L as an IL-33-induced ILC2 costimulatory pathway that licenses local Th2/Treg expansion in mouse lung type 2 inflammation.

Costimulatory and checkpoint control

ICOS-ligand interaction is required for type 2 innate lymphoid cell function, homeostasis, and induction of airway hyperreactivity supports ICOS-ligand interaction as a regulator of ILC2 function, homeostasis, and AHR.
Tissue-Restricted Adaptive Type 2 Immunity Is Orchestrated by Expression of the Costimulatory Molecule OX40L on Group 2 Innate Lymphoid Cells supports OX40L as a costimulatory ILC2-linked regulator of adaptive type 2 immunity.
ILC2s regulate adaptive Th2 cell functions via PD-L1 checkpoint control adds an ILC2-to-Th2 checkpoint branch in which IL-33/ST2-activated pulmonary ILC2s use PD-L1:PD-1 contact to promote CD4 T-cell GATA3 and IL-13 in mouse helminth-associated type 2 immunity.
Cross-talk between ILC2 and Gata3high Tregs locally constrains adaptive type 2 immunity refines OX40L regulation by showing that ILC2s also support Gata3high Treg accumulation, and that these Tregs feed back to tune OX40L availability and restrain effector-memory Th2 expansion.
In the adaptive-immunity map, lung-direct ILC2 evidence now separates PD-L1-to-Th2 polarization, OX40L-to-Th2/Treg licensing, and Gata3high Treg feedback; see ILC Regulation Of Adaptive Immunity.
Gut ILC2-derived IL-10 adds a regulatory cytokine branch distinct from lung OX40L costimulation; it is useful for ILC2 state diversity but should remain gut-labeled (ILC2s are the predominant source of intestinal ILC-derived IL-10).
The Role of the TL1ADR3 Axis in the Activation of Group 2 Innate Lymphoid Cells in Subjects with Eosinophilic Asthma supports TL1A/DR3 as a human eosinophilic-asthma-linked ILC2 activation axis.
PD-1 pathway regulates ILC2 metabolism and PD-1 agonist treatment ameliorates airway hyperreactivity supports PD-1 as a metabolic checkpoint that limits ILC2 viability and effector function.

Metabolic regulation

Autophagy is critical for group 2 innate lymphoid cell metabolic homeostasis and effector function supports autophagy as a regulator of ILC2 metabolic balance, proliferation, apoptosis, and cytokine secretion.
Dichotomous metabolic networks govern human ILC2 proliferation and function supports a human baseline-versus-activated metabolic split in which circulating ILC2s rely on amino-acid-supported OXPHOS at rest but use glycolysis and mTOR for IL-33-driven effector activation.
Blocking the HIF-1alpha glycolysis axis inhibits allergic airway inflammation by reducing ILC2 metabolism and function supports HIF-1alpha/glycolysis as a pro-inflammatory ILC2 metabolic axis in allergic airway inflammation.
Regulation of type 2 innate lymphoid cell-dependent airway hyperreactivity by butyrate supports butyrate/HDAC-linked suppression of ILC2 cytokine output and ILC2-dependent airway hyperreactivity in the reported systems.
Aryl Hydrocarbon Receptor Signaling Cell Intrinsically Inhibits Intestinal Group 2 Innate Lymphoid Cell Function adds a gut ILC2 aryl-hydrocarbon-receptor/AHR restraint branch, and Retinoid X receptor gamma dictates the activation threshold of group 2 innate lymphoid cells and limits type 2 inflammation in the small intestine adds an RXRgamma lipid-metabolic activation-threshold branch.
Dopamine inhibits group 2 innate lymphoid cell-driven allergic lung inflammation by dampening mitochondrial activity supports mitochondrial activity as a dopamine-sensitive ILC2 effector-control node.
mTORC1 signaling in group 2 innate lymphoid cells coordinates neuro-immune crosstalk in allergic lung inflammation supports mTORC1 as a link between ILC2 metabolism and neuroimmune crosstalk.
Metabolic features of innate lymphoid cells is useful as review-level orientation for ILC metabolic adaptability, but individual pathway claims should remain anchored to primary sources.
S1P-dependent interorgan trafficking of group 2 innate lymphoid cells supports host defense supports S1P-dependent interorgan trafficking as a mouse inflammatory ILC2 positioning mechanism, separate from steady-state tissue residency.
ILC2-derived LIF licences progress from tissue to systemic immunity supports ILC2-derived LIF as a lung immune-egress regulator through lymphatic endothelial CCL21 and CCR7+ cell migration.

Spatial niche, interferon, and inter-organ regulation

Adventitial Stromal Cells Define Group 2 Innate Lymphoid Cell Tissue Niches supports a stromal niche model in which ASCs provide IL-33/TSLP and receive IL-13-linked reciprocal feedback from ILC2s.
Pulmonary environmental cues drive group 2 innate lymphoid cell dynamics in mice and humans adds a dynamic positioning layer in which pulmonary ILC2s use CCR8-CCL8 and collagen-I-dependent migration cues to navigate inflamed lung tissue.
Innate type 2 lymphocytes trigger an inflammatory switch in alveolar macrophages adds an alveolar niche-remodeling branch in which IL-33-activated ILC2-derived IL-13 converts tissue-resident alveolar macrophages from a PPARgamma-centered homeostatic state toward an IRF4-driven inflammatory program.
Interleukin-33 and Interferon-gamma Counter-Regulate Group 2 Innate Lymphoid Cell Activation during Immune Perturbation and Interferon gamma constrains type 2 lymphocyte niche boundaries during mixed inflammation support IFN-gamma as both a functional brake on IL-33-driven ILC2 activation and a spatial brake on ILC2/Th2 tissue dispersion.
Toll-like receptor 9-dependent interferon production prevents group 2 innate lymphoid cell-driven airway hyperreactivity connects microbial/TLR9 sensing to type I IFN, NK-derived IFN-gamma, ILC2 STAT1 signaling, and suppressed AHR.
Maturation and specialization of group 2 innate lymphoid cells through the lung-gut axis adds CCR2/CCR4-defined tissue specialization and IL-33-induced lung-gut movement as a developmental and inflammatory regulation layer.

Neuroimmune and neurotransmitter regulation

The neuropeptide NMU amplifies ILC2-driven allergic lung inflammation supports NMU/NMUR1 as a pro-inflammatory neuroimmune amplifier of ILC2-driven allergic lung inflammation in mouse models.
Neuromedin-U Mediates Rapid Activation of Airway Group 2 Innate Lymphoid Cells in Mild Asthma supports the NMU/NMUR1 axis as a rapid airway ILC2 activation pathway in mild asthma challenge settings.
Cannabinoid receptor 2 engagement promotes group 2 innate lymphoid cell expansion and enhances airway hyperreactivity supports CB2 signaling as a positive receptor-level amplifier of activated ILC2 function and airway hyperreactivity.
Basophils prime group 2 innate lymphoid cells for neuropeptide-mediated inhibition supports cell-cell priming of ILC2s for neuropeptide-mediated inhibition.
PAC1 constrains type 2 inflammation through promotion of CGRP signaling in ILC2s supports PAC1/CGRP-linked negative regulation of type 2 inflammation through ILC2s.
CGRP-related neuropeptide adrenomedullin 2 promotes tissue-protective ILC2 responses and limits intestinal inflammation adds an enteric ADM2-ILC2-AREG tissue-protection branch; it is neuroimmune ILC2 context but not direct lung ADM2 evidence.
beta(2)-adrenergic receptor-mediated negative regulation of group 2 innate lymphoid cell responses supports beta2-adrenergic signaling as an inhibitory ILC2 regulatory axis.
Long-acting muscarinic antagonist regulates group 2 innate lymphoid cell-dependent airway eosinophilic inflammation supports a related but indirect cholinergic branch in which tiotropium restrains ILC2-dependent airway inflammation through basophil M3R signaling.

Stromal, mechanical, and cellular-feedback regulation

Mechanics-activated fibroblasts promote pulmonary group 2 innate lymphoid cell plasticity propelling silicosis progression supports a fibroblast-mechanics axis in which IL-18-producing fibroblasts promote pulmonary ILC2-to-ILC1-like plasticity in silicosis-associated inflammation.
Eosinophils promote effector functions of lung group 2 innate lymphoid cells in allergic airway inflammation in mice supports eosinophils as positive feedback partners that can augment lung ILC2 effector function in allergic airway inflammation.
Tissue signals imprint ILC2 identity with anticipatory function supports the broader principle that local tissue cues can imprint ILC2 identity and prepare context-specific effector capacity.

Infection-conditioned reprogramming

BATF promotes group 2 innate lymphoid cell-mediated lung tissue protection during acute respiratory virus infection supports BATF as a transcriptional regulator that maintains protective ILC2 identity and restricts pathogenic plasticity during acute respiratory viral infection.
Dampening type 2 properties of group 2 innate lymphoid cells by a gammaherpesvirus infection reprograms alveolar macrophages supports viral conditioning as a mechanism that reduces ILC2 type 2 expansion/cytokine output while enabling GM-CSF-dependent monocyte-to-AM imprinting.
Innate lymphoid cells integrate sensing and plasticity to control fungal infections broadens pulmonary infection regulation beyond viruses by showing fungal sensing and cytokine-conditioned ILC2-to-ILC3-like plasticity in a mouse Aspergillus lung infection context.
The molecular and epigenetic mechanisms of innate lymphoid cell (ILC) memory and its relevance for asthma supports a mouse allergen-experienced ILC2 memory branch with epigenetic preparedness after repetitive Alternaria exposure.
Trained immunity and tolerance in innate lymphoid cells, monocytes, and dendritic cells during allergen-specific immunotherapy adds human blood AIT-associated ILC remodeling; it should be used as translational immune-monitoring context rather than direct lung tissue evidence.

Severe-asthma boundary and restraint branches

Human severe-asthma sputum supports an IL-1beta/IL-18-associated ILC2-to-ILC3-like regulatory branch: sort-purified human ILC2s exposed to IL-1beta plus IL-18 upregulate c-kit, IL-17A, and mixed type 2/type 17 transcriptional features in vitro (A population of c-kit+ IL-17A+ ILC2s in sputum from individuals with severe asthma supports ILC2 to ILC3 trans-differentiation).
MSC-mediated suppression and vitamin D3/Blimp-1/IL-10 regulation are useful restraint axes for ILC2 asthma output, but should remain broader immune-regulatory mechanisms rather than ILC2-exclusive pathways (Mesenchymal Stem Cells Suppress Severe Asthma by Directly Regulating Th2 Cells and Type 2 Innate Lymphoid Cells; Vitamin D3 resolved human and experimental asthma via B lymphocyte-induced maturation protein 1 in T cells and innate lymphoid cells).
Severe asthma is characterized by a sex-specific ILC landscape and aberrant airway profile that is suppressed by anti-IL-5/5Ralpha biologics supports a human therapy-response branch in which anti-IL-5/5Ralpha biologics suppress airway IL-5+/IL-13+ ILCs while leaving core ILC subset abundance largely unchanged; this should be framed as airway cytokine-output modulation rather than ILC depletion.

Review-level orientation and tissue boundaries

The group 2 innate lymphoid cell ( ILC 2) regulatory network and its underlying mechanisms, Tissue-Specific Features of Innate Lymphoid Cells, and Plasticity of innate lymphoid cell subsets are useful review-level orientation sources for ILC2 regulatory networks, tissue specificity, and state plasticity.
RORalpha is a critical checkpoint for T cell and ILC2 commitment in the embryonic thymus adds developmental lineage-boundary context for ILC2 identity rather than mature lung disease regulation.
Immunotherapy for asthma is useful for asthma endotype and therapy framing, but ILC-specific claims should remain anchored to ILC-focused primary sources.
Group 2 innate lymphoid cells promote inhibitory synapse development and social behavior is retained as extrapulmonary neuroimmune ILC2 context; it should not be used as lung neuroimmune or asthma evidence without pulmonary data.

Interpretation

ILC2 function is regulated by layered controls rather than a single master pathway. Epithelial alarmins and lipid mediators provide rapid activation, costimulatory and checkpoint receptors tune ILC2-adaptive dialogue, metabolism sets effector capacity, neuroimmune inputs provide fast excitatory or inhibitory control, and infection can redirect ILC2 identity toward repair or niche-imprinting roles. The map below separates positive inputs, negative inputs, and state-rerouting signals so the reader can see both accelerating and restraining branches at a glance.

Activation and effector support

flowchart TB
    accTitle: ILC2 Activation And Effector Support
    accDescr: Compact vertical map of positive ILC2 regulatory inputs and output states.

    cue["Activation cues"]
    alarmin["IL-33 / IL-25"]
    lipid["LTE4 / PGD2"]
    costim["ICOS / OX40L / PD-L1"]
    niche["ASC niche"]
    neuro["NMU / CB2"]
    metabolism["HIF-1a / mTORC1"]
    ilc2["ILC2"]
    type2["IL-5 / IL-13"]
    repair["AREG / GM-CSF"]
    disease["AHR / repair"]

    cue --> alarmin
    cue --> lipid
    cue --> costim
    cue --> niche
    cue --> neuro
    cue --> metabolism
    alarmin --> ilc2
    lipid --> ilc2
    costim --> ilc2
    niche --> ilc2
    neuro --> ilc2
    metabolism --> ilc2
    ilc2 --> type2
    ilc2 --> repair
    type2 --> disease
    repair --> disease

    classDef cue_class fill:#e8f3ff,stroke:#3b6ea8,stroke-width:2px,color:#17324d
    classDef cell_class fill:#fff4de,stroke:#b47a1f,stroke-width:2px,color:#4a3108
    classDef out_class fill:#eef7ed,stroke:#4d8a50,stroke-width:2px,color:#173d1d
    class cue,alarmin,lipid,costim,niche,neuro,metabolism cue_class
    class ilc2 cell_class
    class type2,repair,disease out_class

Brakes and restraint

flowchart TB
    accTitle: ILC2 Brakes And Restraint
    accDescr: Compact vertical map of inhibitory ILC2 regulatory inputs.

    brakes["Restraint cues"]
    interferon["IFN axis"]
    pd1["PD-1"]
    treg["Gata3high Treg"]
    dp2["DP2 block"]
    metabolic["Butyrate / dopamine"]
    neural["PAC1 / beta2-AR"]
    il1b["IL-1beta brake"]
    viral["Viral dampening"]
    ilc2["ILC2"]
    lower["Lower type 2 output"]

    brakes --> interferon
    brakes --> pd1
    brakes --> treg
    brakes --> dp2
    brakes --> metabolic
    brakes --> neural
    brakes --> il1b
    brakes --> viral
    interferon -.-> ilc2
    pd1 -.-> ilc2
    treg -.-> lower
    dp2 -.-> ilc2
    metabolic -.-> ilc2
    neural -.-> ilc2
    il1b -.-> ilc2
    viral -.-> ilc2
    ilc2 -.-> lower

    classDef brake fill:#f4f4f4,stroke:#777,stroke-width:1px,color:#222
    classDef cell fill:#fff4de,stroke:#b47a1f,stroke-width:2px,color:#4a3108
    classDef output fill:#eef7ed,stroke:#4d8a50,stroke-width:2px,color:#173d1d
    class brakes,interferon,pd1,treg,dp2,metabolic,neural,il1b,viral brake
    class ilc2 cell
    class lower output

Plasticity and rerouting

flowchart TB
    accTitle: ILC2 Plasticity And Rerouting
    accDescr: Compact vertical map of ILC2 state rerouting and boundary-state cues.

    ilc2["ILC2"]
    cytokines["IL-1b / IL-18"]
    type17["c-kit / IL-17A"]
    nasal["IL-23 / TGF-beta"]
    mechanics["IL-18 fibroblast"]
    ilc1like["T-bet / IFN-g"]
    lunggut["lung-gut axis"]
    specialized["tissue imprint"]

    ilc2 --> cytokines --> type17
    ilc2 --> nasal --> type17
    ilc2 --> mechanics --> ilc1like
    ilc2 --> lunggut --> specialized

    classDef cell fill:#fff4de,stroke:#b47a1f,stroke-width:2px,color:#4a3108
    classDef cue fill:#f6eefc,stroke:#7a55a3,stroke-width:2px,color:#2d1645
    classDef state fill:#eef7ed,stroke:#4d8a50,stroke-width:2px,color:#173d1d
    class ilc2 cell
    class cytokines,nasal,mechanics,lunggut cue
    class type17,ilc1like,specialized state

Contradiction and supersession

Contradiction: some pathways activate ILC2s in one context but restrain them in another. For example, neuroimmune inputs include both NMU activation and beta2-adrenergic, dopamine, or PAC1/CGRP inhibitory branches.
Contradiction: metabolic activation can be required for effector function but can also define pathogenic inflammatory states.
Contradiction: infection can activate ILC2-mediated AHR, promote BATF-linked repair, or dampen type 2 properties depending on viral model and timing.
Supersession: no single regulatory pathway supersedes the others. The working model is multi-layered and context-specific.

Open questions

Which regulatory layer is most measurable in the user's data: cytokines, receptor expression, metabolism, neuroimmune genes, or plasticity markers?
Does the project have protein-level evidence for ILC2 cytokine output, or only transcript/marker evidence?
Are ILC2 metabolic claims based on direct assays, pathway scores, or inferred signatures?
Are neuroimmune signals measured in ILC2s, neurons, epithelial cells, or tissue-level ligand expression?
Which regulatory node should be prioritized experimentally: IL-33/ST2, lipid mediators, PD-1, HIF-1alpha/glycolysis, mTORC1, BATF, or GM-CSF?

Future Expansion Directions

This short appendix highlights future literature directions rather than current mechanistic conclusions. The most useful additions for later versions of this page would be:

Additional ILC2 metabolic sources that separate direct metabolic assays from transcriptomic or pathway-score inference.
More neuroimmune ILC2 sources that clarify excitatory versus inhibitory pathways across receptor contexts and tissues.
A tighter source-linked table connecting each ILC2 regulatory mechanism to disease outcome, species, assay type, and directness of evidence.